1A7 mAb

1A7 mAb is a monoclonal antibody that specifically targets a novel 6-O-highly sulfated heparan sulfate (6O-HS) oligosaccharide found on tumor-associated blood vessels and certain immune cells. This 6O-HS epitope serves as a ligand for the GPNMB receptor, which is known to promote tumor angiogenesis and inhibit T cell activation. By binding to 6O-HS, 1A7 mAb blocks the interaction between GPNMB and heparan sulfate proteoglycans (HSPGs) such as syndecan-4, thereby reversing GPNMB-mediated immunosuppression and pro-angiogenic signaling. In preclinical models of renal cell carcinoma (RCC), 1A7 mAb has demonstrated significant anti-tumor activity, reducing microvessel density and myeloid-derived suppressor cell (MDSC) infiltration while increasing T cell recruitment to the tumor microenvironment. Its efficacy in these models has been shown to be comparable to or greater than established checkpoint inhibitors like nivolumab.

Other names

anti-6O-HS mAbanti6O-HS mAbanti 6O-HS mAb